EUVIMEDEUVIMED entdecken
Crossref

Tuberculosis screening in patients with hidradenitis suppurativa on tumour necrosis factor inhibitors: a retrospective chart review

Katherine G Byrnes iD, Richard H Flowers

Clinical and Experimental Dermatology · 2025

DOI: 10.1093/ced/llaf014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2025. Verfasst von Katherine G Byrnes und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Virginia School of Medicine, Charlottesville, VA, USA. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Latent Tuberculosis, Infliximab, Adalimumab. Die Arbeit nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with hidradenitis suppurativa (HS) treated with tumour necrosis factor (TNF) inhibitors are at an increased risk for tuberculosis (TB) reactivation, necessitating baseline latent TB infection (LTBI) screening. However, evidence regarding the value of periodic LTBI screening in this population is limited. In this single-centre retrospective chart review, we investigated the LTBI rate in patients with HS treated with the TNF inhibitors adalimumab or infliximab. The cohort included 92 patients with a median treatment duration of 30 months (range 3–175) and a median interferon-gamma release assay number of 3 (range 1–8). The cumulative observation time was 286 person-years. Our investigation found no positive LTBI results in patients with HS on TNF inhibitors, challenging clinicians to reconsider the utility of serial screening for such patients who are otherwise at low risk for TB. Further research is essential for the development of evidence-based guidelines to optimize patient care and healthcare resource allocation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaLatent TuberculosisInfliximabAdalimumabTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsHumansRetrospective StudiesMaleAdultFemaleMiddle AgedMass ScreeningInterferon-gamma Release TestsYoung Adult

Substanzen

InfliximabAdalimumabTumor Necrosis Factor-alphaTumor Necrosis Factor Inhibitors

Autor:innen und Institutionen

  • University of Virginia School of Medicine, Charlottesville, VA, USA.
  • Department of Dermatology, University of Virginia, Charlottesville, VA, USA.

ORCID-Profile: Katherine G Byrnes

Zitieren

APA

Byrnes, K. G., & Flowers, R. H. (2025). Tuberculosis screening in patients with hidradenitis suppurativa on tumour necrosis factor inhibitors: a retrospective chart review. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llaf014

Vancouver

Byrnes KG, Flowers RH. Tuberculosis screening in patients with hidradenitis suppurativa on tumour necrosis factor inhibitors: a retrospective chart review. Clinical and Experimental Dermatology. 2025. doi:10.1093/ced/llaf014

BibTeX
@article{Byrnes2025,
  author = {Byrnes, Katherine G and Flowers, Richard H},
  title = {Tuberculosis screening in patients with hidradenitis suppurativa on tumour necrosis factor inhibitors: a retrospective chart review},
  journal = {Clinical and Experimental Dermatology},
  year = {2025},
  doi = {10.1093/ced/llaf014}
}
Kostenlos starten →